Fresenius Kabi Introduces Glucagon for Injection

Lake Zurich, Ill., July 27, 2015 – Fresenius Kabi announced today the introduction of Glucagon for Injection in the United States. Fresenius Kabi is a global health care company that specializes in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition.

Fresenius Kabi Glucagon for Injection is indicated for use as a diagnostic aid during radiologic examinations and is available in 10-packs of 1mg vials.

“Glucagon for Injection is the newest addition to our expanding portfolio of specialty injectable products,” said John Ducker, president and CEO of Fresenius Kabi USA. “We are committed to offering customers a broad portfolio and exceptional service, and we’re pleased to now offer another choice for Glucagon.”

About Fresenius Kabi
Fresenius Kabi (www.fresenius-kabi.us) is a global health care company that specializes in medicines and technologies for infusion, transfusion and clinical nutrition. The company’s products and services are used to help care for critically and chronically ill patients. The company’s U.S. headquarters is in Lake Zurich, Illinois. The company’s global headquarters is in Bad Homburg, Germany.

For more information about Fresenius Kabi worldwide, please visit www.fresenius-kabi.com.

Contacts
Matt Kuhn
847-550-5751
matt.kuhn@fresenius-kabi.com